Home/Filings/4/0001179110-14-001389
4//SEC Filing

ProUroCare Medical Inc. 4

Accession 0001179110-14-001389

CIK 0001222244operating

Filed

Jan 26, 7:00 PM ET

Accepted

Jan 27, 10:33 AM ET

Size

22.6 KB

Accession

0001179110-14-001389

Insider Transaction Report

Form 4
Period: 2014-01-15
Transactions
  • Purchase

    Common Stock Warrant (right to buy)

    2014-01-15+75,00075,000 total
    Exercise: $0.50From: 2014-01-15Exp: 2016-10-01Common Stock (75,000 underlying)
  • Purchase

    10% Convertible Promissory Note

    2014-01-15$1.00/sh
    Exercise: $0.50From: 2014-01-15Exp: 2015-10-01Common Stock
Holdings
  • Warrants

    Exercise: $0.50From: 2013-09-20Exp: 2017-03-31Common Stock (100,000 underlying)
    100,000
  • Convertible Note

    Exercise: $0.50From: 2013-07-01Exp: 2014-07-01Common Stock
  • Common Stock, $0.00001 par value

    1,116,080
  • Warrants

    Exercise: $0.50From: 2013-05-08Exp: 2018-05-08Common Stock, $0.00001 par value (145,998 underlying)
    145,998
  • Warrants

    Exercise: $0.50From: 2013-05-08Exp: 2018-05-08Common Stock, $0.00001 par value (295,313 underlying)
    295,313
  • Warrants

    Exercise: $0.50From: 2013-09-20Exp: 2016-09-20Common Stock (100,000 underlying)
    100,000
  • Convertible Note

    Exercise: $1.30Exp: 2015-03-31Common Stock, $0.00001 par value
  • Warrant

    Exercise: $0.50From: 2013-07-01Exp: 2016-07-01Common Stock (100,000 underlying)
    100,000
  • Warrants

    Exercise: $0.50From: 2013-05-08Exp: 2018-05-08Common Stock, $0.00001 par value (291,670 underlying)
    291,670
  • Convertible Note

    Exercise: $1.30Exp: 2014-09-20Common Stock, $0.00001 par value
Footnotes (10)
  • [F1]The Reporting Person holds $100,000 of 10% convertible secured subordinated promissory notes from the Issuer. The promissory note and any accrued interest thereon is convertible at any time at the option of the reporting person into common stock at $1.30 per share. The number of shares to be issued upon conversion will be fixed on the conversion date and reported on a Form 4 within 2 business days after conversion. The Issuer's directors specifically approved the reporting person's participation in the private placement as exempt from the requirements of Section 16b as provided by Rules 16b-3(d) and 16b-3(e).
  • [F10]Subject to adjustment based on a predefined formula set forth in the 10% Secured Convertible Note.
  • [F2]The issuer issued the warrants to the Reporting Person as consideration for a $450,000 loan guarantee for the period from April 1, 2013 to February 15, 2014. The warrants will vest as to 28,125 shares on the first of each month from April 2013 to January, 201], and as to 14,063 shares on February 1, 2014, subject to adjustment if the amount of the loan guaranteed should change. The issuer's Board of Directors specifically approved the reporting person's participation in the private placement as exempt from the requirements of Section 16b as provided by Rules 16b-3(d) and 16b-3(e).
  • [F3]The Reporting Person agreed to accept the warrants in lieu of cash repayment of $56,833 of advances made by the Reporting Person to the Issuer. The Issuer's Board of Directors specifically approved the reporting person's participation in the private placement as exempt from the requirements of Section 16b as provided by Rules 16b-3(d) and 16b-3(e).
  • [F4]The issuer issued the warrants to the Reporting Person as consideration for a $500,000 loan guarantee for the period from November 1, 2012 to March 31, 2013. The Issuer's Board of Directors specifically approved the reporting person's participation in the private placement as exempt from the requirements of Section 16b as provided by Rules 16b-3(d) and 16b-3(e).
  • [F5]Currently exercisable in full.
  • [F6]The Issuer issued the warrants to the Reporting Person as consideration for extending the expiration date of the Convertible Note for a period of one year to September 20, 2014.
  • [F7]The Issuer issued the warrants to the Reporting Person as consideration for extending the expiration date of the Convertible Note for a period of one year to March 31, 2015.
  • [F8]On January 15, 2014, the reporting person purchased $25,000, 10% secured convertible promissory note from the issuer in a private placement. The promissory note matures on October 1, 2015, however, the holders have an optional conversion at any time prior to maturity at an exercise price predetermined by a formula set forth in the promissory note.
  • [F9]The number of underlying common shares of the issuer will determined at the time of conversion based on a predefined formula set forth in the promissory note.

Issuer

ProUroCare Medical Inc.

CIK 0001222244

Entity typeoperating
IncorporatedNV

Related Parties

1
  • filerCIK 0001222244

Filing Metadata

Form type
4
Filed
Jan 26, 7:00 PM ET
Accepted
Jan 27, 10:33 AM ET
Size
22.6 KB